Who are Carboplatin+Paclitaxel's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Cisplatin, paclitaxel, Carboplatin plus Paclitaxel, Combination carboplatin and paclitaxel, Cisplatin and Docetaxel, carboplatin and nab paclitaxel.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/carboplatin-paclitaxel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Carboplatin+Paclitaxel — Competitive Intelligence Brief

Carboplatin+Paclitaxel (Carboplatin+Paclitaxel) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Chemotherapy combination (platinum agent + taxane). Area: Oncology.

phase 3 Chemotherapy combination (platinum agent + taxane) DNA (carboplatin); beta-tubulin (paclitaxel) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Carboplatin+Paclitaxel (Carboplatin+Paclitaxel) — AstraZeneca. Carboplatin and paclitaxel work together as a chemotherapy combination: carboplatin cross-links DNA to prevent replication, while paclitaxel stabilizes microtubules to disrupt cell division.

Comparator set (5 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Carboplatin+Paclitaxel TARGET	Carboplatin+Paclitaxel	AstraZeneca	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)
Cisplatin, paclitaxel	Cisplatin, paclitaxel	Karolinska University Hospital	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (cisplatin); β-tubulin/microtubules (paclitaxel)
Carboplatin plus Paclitaxel	Carboplatin plus Paclitaxel	The University of Hong Kong	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); beta-tubulin (paclitaxel)
Combination carboplatin and paclitaxel	Combination carboplatin and paclitaxel	OSI Pharmaceuticals	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); β-tubulin (paclitaxel)
Cisplatin and Docetaxel	Cisplatin and Docetaxel	Swiss Cancer Institute	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (cisplatin); beta-tubulin (docetaxel)
carboplatin and nab paclitaxel	carboplatin and nab paclitaxel	Shanghai Henlius Biotech	phase 3	Chemotherapy combination (platinum agent + taxane)	DNA (carboplatin); β-tubulin (nab-paclitaxel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Chemotherapy combination (platinum agent + taxane) class)

AstraZeneca · 1 drug in this class
Karolinska University Hospital · 1 drug in this class
OSI Pharmaceuticals · 1 drug in this class
Shanghai Henlius Biotech · 1 drug in this class
Swiss Cancer Institute · 1 drug in this class
The University of Hong Kong · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Carboplatin+Paclitaxel — Competitive Intelligence Brief. https://druglandscape.com/ci/carboplatin-paclitaxel. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab